

WORLDWIDE REGISTRATION

Cabotegravir PrEP

APPROVAL

US
Australia
Zimbabwe
South Africa
Malawi
Botswana
Brazil
Philippines
Zambia
European Medicines Agency (EMA)
Malaysia
Peru
Nigeria

SUBMISSION

Kenya	Colombia
Uganda	Ivory Coast
Vietnam	Mozambique
Myanmar	Rwanda
China	Tanzania
Thailand	Great Britain
Ukraine	Canada
Namibia	

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 27 October 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.